How GammaDelta's T cells could become the newest cancer immunotherapy class
Today's launch of Abingworth-backed GammaDelta Therapeutics Ltd. could signal the rise of γδ T cells as the newest class of cancer immunotherapies. The company is the second founded in as many years to capitalize on the small subclass that Abingworth believes could outstrip the more common αβ T cells filling company pipelines.
Abingworth will incubate GammaDelta in its London offices and is providing an undisclosed amount of seed funding.
According to founder and interim CEO Raj Mehta, the company was formed around a technology from γδ T cell pioneer Adrian Hayday that enables isolation of tissue-resident γδ T cells - a subset of T cells believed to penetrate and kill tumors better than their blood-resident counterparts. Mehta is also business development executive at Cancer Research Technology Ltd.
Hayday is a professor at King's College London and a group leader at Cancer Research UK and the Francis Crick Institute. GammaDelta licensed IP covering Hayday's technology, which was jointly owned by the three institutions.
The newco comes a year after Gadeta B.V.